June 25, 2018December 6, 2018

Kymriah Ellicits Prolonged Complete Responses in Advanced DLBCL Patients, Trial Data Show

News

Kymriah (tisagenlecleucel), a chimeric antigen receptor (CAR) T-cell therapy developed by Novartis, is able to ellicit prolonged complete responses with minor side effects in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according ... Read more

June 22, 2018

Duvelisib Effective in Relapsed or Refractory CLL/SLL Patients Who Failed Arzerra, Extension Study Shows

News

Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who failed prior Arzerra (ofatumumab) treatment achieved robust and durable responses after switching to duvelisib, Verastem Oncology announced. Results from the Phase 3 crossover extension study IPI-145-12 (NCT02049515) ... Read more